title: Limitation of portal vein embolization for extension of hepatectomy indication in patients with hepatocellular carcinoma.
abstract: OBJECTIVE
  Although percutaneous trans-hepatic portal vein embolization (PTPE) expands the candidate pool for hepatectomy in patients with hepatobiliary malignancies, the role of PTPE in patients with active hepatitis or cirrhosis has yet to be determined.
  
  
  METHODS
  Records of patients who underwent PTPE of the right portal vein between 1984 and April 2001 were reviewed retrospectively. To determine the indication for PTPE and subsequent hepatectomy, clinical variables, including serum concentrations of hyaluronic acid (HA), procollagen type III peptide (P-III-P), and the 7S domain of type IV collagen (7S-IV), were compared between patients who underwent right hepatectomy (group A; n=44) and the other patients (group B; n=17).
  
  
  RESULTS
  The scores for prediction of postoperative liver failure (prediction score) and serum HA and P-III-P concentrations were different in the two groups. Thirteen of 30 patients (43%) whose prediction score was more than 50, the limit of the hepatectomy without PTPE, successfully underwent right hepatectomy following PTPE. The resectability ratios increased to 75% and 100%, when the HA concentration was < or = 100mg/L and the P-III-P concentration < or = 0.7/mL.
  
  
  CONCLUSIONS
  Serum HA and P-III-P concentrations are useful guidelines for identifying candidates for right hepatectomy following PTPE.
authors.affiliation: Gastroenterological and Hepato-Biliary-Pancreatic Surgery Osaka City University Graduate School of Medicine, Osaka, Japan. m2664791@msic.med.osaka-cu.ac.jp
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Hirohashi
authors.forename: Hiromu
authors.initials: H
authors.lastname: Tanaka
authors.forename: Tadashi
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Shoji
authors.initials: S
authors.lastname: Kubo
authors.forename: Taichi
authors.initials: T
authors.lastname: Shuto
authors.forename: Shigekazu
authors.initials: S
authors.lastname: Takemura
authors.forename: Takatsugu
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Akishige
authors.initials: A
authors.lastname: Kanazawa
authors.forename: Masao
authors.initials: M
authors.lastname: Ogawa
authors.forename: Harushi
authors.initials: H
authors.lastname: Osugi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kinoshita
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000601:surgery* / Q000628:therapy*; D004621:Embolization, Therapeutic; D005260:Female; D006498:Hepatectomy; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D010446:Peptide Fragments / Q000097:blood; D011169:Portal Vein; D011347:Procollagen / Q000097:blood; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; D006820:Hyaluronic Acid